1. Ocular Therapeutix Inc. (NASDAQ:OCUL)
Number of Hedge Fund Holders: 49
Market Capitalization: $1.48 billion
Share Price: $6.72
Ocular Therapeutix, Inc. (NASDAQ: OCUL) leads this ranking by hedge-fund ownership, even after a difficult year for its shares. According to the supplied market data, the stock had declined nearly 43% in 2026 as investors weighed the prospects and competitive challenges facing its retinal disease program.
The principal asset is AXPAXLI, an investigational sustained-delivery treatment for wet age-related macular degeneration. Its commercial proposition centers on maintaining disease control while reducing the frequency of treatment, an important consideration for patients facing repeated eye injections and monitoring visits.
The company’s second-quarter update outlined plans to submit a new drug application in the fourth quarter of 2026. The proposed filing would draw on SOL-1 efficacy and safety data, interim SOL-R safety findings, and supporting evidence.
A regulatory submission would be a significant development milestone, although acceptance, review, and approval remain separate steps. Commercial success would also require evidence that the treatment offers a compelling benefit in a competitive retinal disease market.
UBS initiated coverage with a Buy rating and a $14 price target, according to the supplied analyst material. Its longer-term model projected that AXPAXLI could generate as much as $3.3 billion in sales by 2035, an estimate dependent on successful development, approval, and market adoption.
The company reported a June 30 cash balance of $598.6 million and projected funding into 2028, providing resources for regulatory work and commercial preparation. Those resources strengthen execution capacity, while development expenses and persistent losses remain part of the investment equation.
Ranking rationale: Ocular Therapeutix, Inc. (NASDAQ: OCUL) holds first place with 49 hedge-fund holders, the highest count among the selected stocks. Its lead position reflects institutional ownership within this screen, supported by AXPAXLI’s regulatory pathway and commercial potential, rather than an assurance of superior future returns.
Click here to read the full article: 10 Best Biotech Stocks Under $10 to Buy Now
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
